Patient-specific dosimetry

Details Patient-specific dosimetry Patient-specific dosimetry

2005-08-10

2010-02-23

Clow, Lori A. (Department: 1631)

Data processing: measuring, calibrating, or testing

Measurement system in a specific environment

Biological or biochemical

C424S001370, C424S001490, C530S391300

Reexamination Certificate

active

07668662

ABSTRACT:
A patient-specific optimally effective radiation dose for administration of a radiopharmaceutical to a patient for treatment of a disease may be established by basing the calculation of the appropriate therapeutic dose on factors such as the desired total body dose, the maximum tolerated dose, the typical clearance profile of the radiopharmaceutical, the patient's mass or maximum effective mass, and the patient-specific residence time of the radiopharmaceutical or an analog in the whole body of the patient. The use of the method allows for treatment of a patient with an appropriate dose which is maximally effective against the disease yet minimally toxic. The determination of a patient-specific therapeutic dose may be assisted by the use of a software program set to the particular parameters of the radiopharmaceutical.

REFERENCES:
patent: 4831122 (1989-05-01), Buchsbaum et al.
patent: 6251362 (2001-06-01), Wahl et al.
patent: WO-96/34632 (1996-11-01), None
patent: WO-97/42522 (1997-11-01), None
Benua et al., “The Relation of Radioiodine Dosimetry to Results and Compilations in the Treatment of Metaphysics Thyroid Cancer,” Amer. J. Roentg., 87(1): 171-182 (Jan. 1962).
Brownell et al., “Absorbed Fractions for Photon Dosimetry,” J. Nuclear Medicine, Supp. 1, MIRD Pamphlet No. 3, pp. 28-39 (Feb. 1968).
Carrasquillo et al., “Radioimmunoscintigraphy of Colon Cancer with Iondine-131-Labeled B72.3 Monoclonal Antibody,” J. of Nuclear Medicine, 29: 1022-1030 (Jun. 1988).
Clairand et al., “Dose3D: EGS4 Monte Carlo Code Based Software for International Radionuclide Dosimetry,” J. Nuclear Med., vol. 40: 1517-1523 (Sep. 1999).
Colcher et al., “Quantitative Analyses of Selective Radiolabeled Monoclonal Antibody Localization in Metastatic Lesions of Colorectal Cancer Patients,” Cancer Research, 47: 1185-1189 (Feb. 15, 1987).
Eary et al., “Iodine-131-Labeled Anti-CD20 (B1) Antibody Therapy for Released Non-Hodgkin's Lymphomas: Phase II Trial Results,” The Journal of Nuclear Medicine, Supplemental, 36(5): 214P Abstract No. 963 (May 1995).
Eary et al., “Radioimmunotherapy Treatment Planning Based on Radiation Absorbed Dose or Patient Size,” The Journal of Nuclear Medicine, Supplemental, 37(5): 43P, Abstract No. 162 (May 1996).
Ettinger et al., “Phase I-II Study of Isotopic Immunoglobulin Therapy for Primary Liver Cancer,” Cancer Treatment Reports, 66(2): 289-297 (Feb. 1982).
Furhang et al., “Thyroid Cancer Dosimetry Using Clearance Fitting,” The Journal of Nuclear Medicine, 40(1): 131-136 (Jan. 1999).
Kaminski et al., “Iodine-131-Anti-B1 Radioimmunotherapy for B-cell Lymphoma,” Journal of Clinical Oncology, vol. 14: 1974-1981 (Jul. 1996).
Kaminski et al., “Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-cell Lymphoma,” J. Clinical Oncology, 10(11): 1696-1711 (Nov. 1992).
Kaminski et al., “Radioimmunotherapy of B-cell Lymphoma With (131 I) Anti-B1 (Anti-CD20) Antibody,” The New England Journal of Medicine, 329(7): 459-465 (Aug. 12, 1993).
Koral et al., “CT-SPECT Fusion Plus Conjugate Views for Determining Dosimetry in Iodine-131-Monoclonal Antibody Therapy of Lymphoma Patients,” The Journal of Nuclear Medicine, 35(10): 1714-1720 (Oct. 1994).
Koral et al., “Preliminary Report of Tumor Dosimetry from I-131 SPECT of Previously-Untreated Patients with B-cell Lymphoma,” J. Nuclear Medicine, 39 (5 sppl.): 112P, (May 1998), Abstract No. 437.
Larson et al., “Comparison of Bone Marrow Dosimetry and Toxic Effect of High Dose 131I-Labeled Monoclonal Antibodies Administered to Man,” Int. J. Rad. Appl. Instrum. B. 16(2): 153-158 (1989).
Letvin et al., “Use of Radiolabeled Monoclonal Anti-B1 Antibody for B Lymphocyte Imaging in Rhesus Monkeys,” Int. J. Rad. Appl. Instrum. B. 14(2): 99-105 (1987).
Liu et al., “A Radionuclide Therapy Treatment Planning and Dose Estimation System,” J. Nuclear Med., 40: 1151-1153 (Jul. 1999).
Loevinger et a;., “A Revised Schema for Calculating the Absorbed Dose from Biologically Distributed Radionuclides,” Medical Internal Radiation Dose (MIRD) Committee of the Society of Nuclear Medicine, Pamphlet No. 1, Revised, pp. 3-10 (Mar. 1976).
Malcolm Rowland et al., “Age and Weight” Clinical Pharmacokinetics, Chap. 15, pp. 218-228, Lea & Febiger, Philadelphia, PA, (1980).
Order et al., “Monoclonal Antibodies: Potential Role in Radiation Therapy and Oncology,” I. J. Radiation Oncology Bio. Phys., 8: 1193-1201 (Jul. 1982).
Order et al., “Phase I-II Study of Radiolabeled Antibody Integrated in the Treatment of Primary Hepatic Malignacies,” I. J. Radiation Oncology Bio. Phys., 6: 703-710 (Jun. 1980).
PK Solutions 2.0 Software, “Noncompartmental Pharmacokinetics Data Analysis,” Summit Research Services, Montrose, CO, released Jun. 4, 1997, Online Users Guide.
Rommelfanger et al., “Dosimetry of I-131 Anti-B1 (Anti-CD20) Antibody for Non-Hodgkin's Lymphoma: Comparison of Up-front Treatment vs. Chemotherapy-Refractory Patients,” J. Nuclear Medicine, 39 (5 sppl.): 186P, Abstract No. 840 (May 1998).
Schmidt et al., “Whole-Body Kinetics and Dosimetry of L-3-[123I] Iodo-Alpha-Methyltyrosine,” European J. Nuclear Medicine, 24(9): 1162-1166, (Sep. 1997).
Siegel et al., “Bone Marrow Dosimetry and Toxicity for Radioimmunotherapy,” Antibody, Immunoconjugates, and Radiopharmaceuticals, 3(4): 213-233 (1990).
Siegel et al., “Sacral Scintigraphy for Bone Marrow Dosimetry in Radioimmunotherapy,” Int. J. Rad. Appl. Instrum. B., 16(6): 553-559 (1989).
Toohey et al., “Comparative Analysis of Dosimetry Parameters for Nuclear Medicine,” Int. Radiopharm. Dosim. Symp. Proc. Conf. Meeting date 1996, 2: 532-551 (1996).
Wahl et al., “Dose Escalation in Radioimmunotherapy Based on Projected Whole Body Dose,” J. Nuclear Medicine, 35(5 Sppl): 233P, Abstract No. 952 (1994).
Wahl et al., “Importance of the Terminal Portion of Tumor Time-Activity Curve in Determining Tumor Dosimetry in Radioimmunotherapy,” The Journal of Nuclear Medicine, 32(6): 1314-1315 (Jun. 1991).
Wahl et al., “Patient-Specific Whole-Body Dosimetry: Principles and a Simplified Method for Clinical Implementation,” J. Nuclear Medicine., 39(8 Spll.): 14S-20S, (Aug. 1998).
Wahl et al., “Radioimmunotherapy with I-131-Anti-B-1 for Refractory B-cell Lymphoma: Updated Phase I Study Results,” The Journal of Nuclear Medicine, Supplemental, 36(5): 214P, Abstract No. 961 (May 1995).
Weinstein et al., “Monoclonal Antibodies in the Lymphatics: Toward the Diagnosis and Therapy of Tumor Metastases,” Science, 218: 1334-1337 (Dec. 24, 1982).
Zasadny et al., “A Simplified Method for Determining Therapeutic Activity to Administer for Radioimmunotherapy,” The Journal of Nuclear Medicine, Supplemental, 37 (5): 43P, Abstract No. 163 (May 1996).
Zasadny et al., “Correlation of Dosimetric Parameters with Hematological Toxicity after Radioimmunotherapy of Non-Hodgkin's Lymphoma with I-131 Anti-B1. Utility of a New Parameter: ‘Total Body Dose-Lean’,” The Journal of Nuclear Medicine, Supplemental, 36(5): 214P, Abstract No. 962 (May 1995).
Zasadny et al., “Standardized Uptake Values of Normal Tissues at PET with 2-[Fluorine-18]-Fluoro-2-deoxy-D-glucose: Variations with Body Weight and a Method for Correction,” Radiology, 189(3): 847-850 (Dec. 1993).
Document RSICC Code Package CCC-528, “MIRDOSE 3.1: Code System That Calculates Internal Dose Estimates by the MIRD Technique,” retrieved from http://www-rsicc.ornl.gov/codes/ccc/ccc5/ccc-528.html on Aug. 30, 2001. Abstract dated Mar. 1988, May 1995, Apr. 1998.

Affiliated with

Also associated with

Rating

Patient-specific dosimetry does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Patient-specific dosimetry, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Patient-specific dosimetry will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4171609